



AcureX Therapeutics to present at the Michael J. Fox Foundation Webinar - Innovating from Drug Discovery through the Clinic: Novel Approaches to PD Therapeutic Development on November 10th, 2021.

Webinar Details:

Innovating from Drug Discovery through the Clinic: Novel Approaches to PD Therapeutic Development

This two-day event in November will showcase the latest advances in Parkinson's drug development. Day one will highlight new tools and platforms for drug discovery while day two will feature innovative research programs from the Foundation's funding portfolio. Please note you will have to register separately for each day.

Day 2: Progress in the PD Pipeline: A Snapshot of MJFF's Funded Programs

Wednesday, November 10, 2021 11 a.m. to 12:30 p.m. ET

AcureX Therapeutics Presentation: 8:40 a.m. PT / 11:40 a.m. ET

Halting Neurodegeneration with Miro1 Directed Therapies

Presented by: William Shrader, PhD, Co-founder and CEO, AcureX Therapeutics

Webinar Free Registration

<https://primetime.bluejeans.com/a2m/register/zckhdjga>

About AcureX Therapeutics

The mission of AcureX Therapeutics is to halt neurodegenerative diseases driven by impaired mitophagy, starting with Parkinson's disease. AcureX expects to have one or more late-preclinical therapeutic candidates for Parkinson's in human trials within two years, followed by candidates for other neurodegenerative diseases. AcureX's novel approach and founding intellectual property are based on recent discoveries made by the company's Inventor and Co-founder, Xinnan Wang MD, PhD, Stanford Associate Professor of Neurosurgery. AcureX has built a unique target and drug discovery platform to accelerate drug development and de-risk clinical trials with an exclusive license to the founding intellectual property from Stanford University. The AcureX team is led by veteran scientists with a proven track record in CNS drug development and serial life sciences entrepreneurs. For more information, please visit <https://www.acurex.com>.